Literature DB >> 21315254

Huntington's disease: can mice lead the way to treatment?

Zachary R Crook1, David Housman.   

Abstract

Mouse models for Huntington's Disease (HD) and HD patients demonstrate motor and behavioral dysfunctions, such as progressive loss of coordination and memory, and share similar transcriptional profiles and striatal neuron atrophy. Clear differences between the mouse and human diseases include almost complete striatal degeneration and rarity of intranuclear inclusions in HD, and the fact that mice expressing full-length mutant huntingtin do not demonstrate a shortened life span characteristic of HD. While no clinical interventions tested in mouse models to date have delayed disease progression, the mouse models provide an invaluable tool for both investigating the underlying pathogenic processes and developing new effective therapies. Inherent differences between humans and mice must be considered in the search for efficacious treatments for HD, but the striking similarities between human HD and mouse models support the view that these models are a biologically relevant system to support the identification and testing of potential clinical therapies.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21315254      PMCID: PMC4685469          DOI: 10.1016/j.neuron.2010.12.035

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  144 in total

1.  Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study.

Authors: 
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

2.  A controlled trial of fluoxetine in nondepressed patients with Huntington's disease.

Authors:  P G Como; A J Rubin; C F O'Brien; K Lawler; C Hickey; A E Rubin; R Henderson; M P McDermott; M McDermott; K Steinberg; I Shoulson
Journal:  Mov Disord       Date:  1997-05       Impact factor: 10.338

3.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

Authors:  R Luthi-Carter; A Strand; N L Peters; S M Solano; Z R Hollingsworth; A S Menon; A S Frey; B S Spektor; E B Penney; G Schilling; C A Ross; D R Borchelt; S J Tapscott; A B Young; J H Cha; J M Olson
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

4.  Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.

Authors:  O Hansson; A Petersén; M Leist; P Nicotera; R F Castilho; P Brundin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease.

Authors:  Jeremy M Van Raamsdonk; Jacqueline Pearson; Daniel A Rogers; Ge Lu; Vilte E Barakauskas; Alasdair M Barr; William G Honer; Michael R Hayden; Blair R Leavitt
Journal:  Exp Neurol       Date:  2005-08-29       Impact factor: 5.330

6.  Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation.

Authors:  L Mangiarini; K Sathasivam; A Mahal; R Mott; M Seller; G P Bates
Journal:  Nat Genet       Date:  1997-02       Impact factor: 38.330

7.  Tetrabenazine is neuroprotective in Huntington's disease mice.

Authors:  Hongyu Wang; Xi Chen; Yuemei Li; Tie-Shan Tang; Ilya Bezprozvanny
Journal:  Mol Neurodegener       Date:  2010-04-26       Impact factor: 14.195

8.  Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.

Authors:  A Jennifer Morton; Dervila Glynn; Wendy Leavens; Zhiguang Zheng; Richard L M Faull; Jeremy N Skepper; James M Wight
Journal:  Neurobiol Dis       Date:  2008-12-11       Impact factor: 5.996

9.  Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.

Authors:  Liliana Menalled; Bassem F El-Khodor; Monica Patry; Mayte Suárez-Fariñas; Samantha J Orenstein; Benjamin Zahasky; Christina Leahy; Vanessa Wheeler; X William Yang; Marcy MacDonald; A Jennifer Morton; Gill Bates; Janet Leeds; Larry Park; David Howland; Ethan Signer; Allan Tobin; Daniela Brunner
Journal:  Neurobiol Dis       Date:  2009-05-21       Impact factor: 5.996

10.  Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease.

Authors:  A Hodges; G Hughes; S Brooks; L Elliston; P Holmans; S B Dunnett; L Jones
Journal:  Genes Brain Behav       Date:  2007-08-13       Impact factor: 3.449

View more
  96 in total

1.  Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex.

Authors:  Adam G Walker; Jason R Ummel; George V Rebec
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

Review 2.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

Review 3.  Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.

Authors:  Tz-Chuen Ju; Yow-Sien Lin; Yijuang Chern
Journal:  Cell Mol Life Sci       Date:  2012-05-25       Impact factor: 9.261

4.  Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington's disease.

Authors:  Motomasa Tanaka; Koko Ishizuka; Yoko Nekooki-Machida; Ryo Endo; Noriko Takashima; Hideyuki Sasaki; Yusuke Komi; Amy Gathercole; Elaine Huston; Kazuhiro Ishii; Kelvin Kai-Wan Hui; Masaru Kurosawa; Sun-Hong Kim; Nobuyuki Nukina; Eiki Takimoto; Miles D Houslay; Akira Sawa
Journal:  J Clin Invest       Date:  2017-03-06       Impact factor: 14.808

Review 5.  Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

Authors:  Anthony W S Chan
Journal:  ILAR J       Date:  2013

6.  Cryopreservation of transgenic Huntington's disease rhesus macaque sperm-A Case Report.

Authors:  Kittiphong Putkhao; Anthony W S Chan; Yuksel Agca; Rangsun Parnpai
Journal:  Cloning Transgenes       Date:  2013

Review 7.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

8.  Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis.

Authors:  Guohao Wang; Xudong Liu; Marta A Gaertig; Shihua Li; Xiao-Jiang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-07       Impact factor: 11.205

9.  Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.

Authors:  Qian Ma; Jianmin Yang; Thomas Li; Teresa A Milner; Barbara L Hempstead
Journal:  Neurobiol Dis       Date:  2015-08-15       Impact factor: 5.996

10.  Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease.

Authors:  Robert G Mealer; Srinivasa Subramaniam; Solomon H Snyder
Journal:  J Neurosci       Date:  2013-02-27       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.